Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22461269 | 1.00 | KIF11 (0.55) | KIF11ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL22461277 | 0.91 | KIF11 (0.45) | KIF11ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL22461281 | 0.91 | KIF11 (0.45) | KIF11ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL22460962 | 0.88 | KIF11 (0.48) | KIF11ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL22460956 | 0.88 | KIF11 (0.48) | KIF11ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL24490179 | 0.87 | KIF11 (0.50) | KIF11ESR1ESR2 | |
| SCHEMBL29358133 | 0.87 | KIF11 (0.50) | KIF11ESR1ESR2 | |
| SCHEMBL24490183 | 0.87 | KIF11 (0.50) | KIF11ESR1ESR2 | |
| SCHEMBL22460925 | 0.87 | DRD1 (0.50) | KIF11ESR1ESR2DRD2DRD1 | |
| SCHEMBL22460978 | 0.87 | DRD1 (0.50) | KIF11ESR1ESR2DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086194-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Suvalent Therapeutics, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
| WO-2020191151-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | KIF11 3058/4885ESR1 741/4885ESR2 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.